vTv Therapeutics (VTVT) Gains from Investment Securities (2023 - 2026)
vTv Therapeutics (VTVT) reported Gains from Investment Securities of -$24000.0 for Q1 2026, down 241.18% on a YoY basis from $17000.0 in Q1 2025, and down 118.6% sequentially from $129000.0 in Q4 2025.
vTv Therapeutics (VTVT) Gains from Investment Securities (2023 - 2026) Analysis & Trends
vTv Therapeutics (VTVT) has 4 years of Gains from Investment Securities data on file, last reported at -$24000.0 in Q1 2026.
- For the quarter ending Q1 2026, Gains from Investment Securities fell 241.18% year-over-year to -$24000.0; the trailing twelve-month figure through Mar 2026 stood at $68000.0 (up 133.33% YoY), and the FY2025 full-year result was $109000.0, down 27.33% from the prior year.
- Gains from Investment Securities fell to -$24000.0 in Q1 2026, from $129000.0 in the prior quarter.
- In the past five years, Gains from Investment Securities ranged from a high of $371000.0 in Q1 2024 to a low of -$574000.0 in Q4 2023.
- A 4-year average of -$24909.1 and a median of -$23000.0 in 2024 frame the typical range for Gains from Investment Securities.
- Across the five-year window, Gains from Investment Securities soared 660.87% in 2025 and tumbled 241.18% in 2026, its largest moves.
- Tracing VTVT's Gains from Investment Securities over 4 years: stood at -$574000.0 in 2023, then soared by 95.99% to -$23000.0 in 2024, then soared by 660.87% to $129000.0 in 2025, then plunged by 118.6% to -$24000.0 in 2026.
- Business Quant data shows VTVT's Gains from Investment Securities at -$24000.0 in Q1 2026, $129000.0 in Q4 2025, and -$25000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - |
| 10 | vTv Therapeutics | 19.21 Mn | 19.21 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -24,000.00 |
| Mar 31, 2026 | -24,000.00 |
| Dec 31, 2025 | 129,000.00 |
| Dec 31, 2025 | 129,000.00 |
| Sep 30, 2025 | -25,000.00 |
| Sep 30, 2025 | -25,000.00 |
| Jun 30, 2025 | -12,000.00 |
| Jun 30, 2025 | -12,000.00 |
| Mar 31, 2025 | 17,000.00 |
| Mar 31, 2025 | 17,000.00 |
| Dec 31, 2024 | -23,000.00 |
| Dec 31, 2024 | -23,000.00 |
| Sep 30, 2024 | -77,000.00 |
| Sep 30, 2024 | -77,000.00 |
| Jun 30, 2024 | -121,000.00 |
| Jun 30, 2024 | -121,000.00 |
| Mar 31, 2024 | 371,000.00 |
| Mar 31, 2024 | 371,000.00 |
| Dec 31, 2023 | -574,000.00 |
| Dec 31, 2023 | -574,000.00 |